Company News 13 Feb 2024 Orthocell submits Singapore Regulatory Application for Remplirâ„¢ Orthocell has today announced that the Company has submitted a regulatory application to the Health Services Authority of Singapore for… Orthocell
Company News 15 Jan 2024 The Hon Kim Beazley AC Joins Orthocell Board Orthocell has appointed Australia’s former US ambassador and Governor of Western Australia, The Hon Kim Beazley AC, as an Independent… Orthocell
Company News 14 Nov 2023 Positive clinical results for OrthoATIâ„¢ Orthocell has today released positive results from our clinical study comparing OrthoATIâ„¢ to surgery for the treatment of severe chronic… Orthocell
Company News 25 Oct 2023 Professor Fiona Wood AM joins Orthocell Board Orthocell has today announced the appointment of one of Australia’s most innovative and respected plastic and reconstructive surgeons and researchers,… Orthocell
Company News 17 Oct 2023 Quarterly Report – Period To 30 September 2023 Orthocell has today published its Quarterly Report for the period ended 30 September 2023. Orthocell
Company News 24 Aug 2023 Striate+â„¢ re-certified under new European medical device regulations Orthocell has announced that Striate+â„¢dental membrane has received regulatory approval under the new European Medical Device Regulations (MDR). Orthocell
Company News 03 Jul 2023 Inaugural Nerve Transfer and Reconstruction Symposium Orthocell was delighted to co-sponsor the inaugural Nerve Transfer and Reconstruction Symposium at the University of Western Australia last week. Orthocell
Company News 29 May 2023 New Bio-manufacturing Facility Launch Event This week marks the official launch of Orthocell’s new GMP certified bio-manufacturing facility at the Company headquarters in Perth. Orthocell
Company News 29 May 2023 Appointment of John Van Der Wielen as Independent Non-Executive Chairman Orthocell has announced the appointment of Mr. John Van Der Wielen as Orthocell’s new independent Non-Executive Chairman, effective June 1,… Orthocell
Company News 26 Apr 2023 Veritas Securities Equity Research Report | April 2023 Veritas Securities Limited has released an Equity Research report valuing Orthocell (ASX: OCC) at A$0.90 per share. The report summarises… Orthocell